These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

578 related articles for article (PubMed ID: 30685678)

  • 41. Atrial arrhythmia prevalence and characteristics for human immunodeficiency virus-infected persons and matched uninfected controls.
    Sanders JM; Steverson AB; Pawlowski AE; Schneider D; Achenbach CJ; Lloyd-Jones DM; Feinstein MJ
    PLoS One; 2018; 13(3):e0194754. PubMed ID: 29558525
    [TBL] [Abstract][Full Text] [Related]  

  • 42. HMG-CoA reductase inhibitors (statins) use and risk of non-Hodgkin lymphoma in HIV-positive persons.
    Chao C; Xu L; Abrams DI; Towner WJ; Horberg MA; Leyden WA; Silverberg MJ
    AIDS; 2011 Sep; 25(14):1771-7. PubMed ID: 21681055
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Risk of recurrent venous thromboembolism in patients with HIV infection: A nationwide cohort study.
    Rokx C; Borjas Howard JF; Smit C; Wit FW; Pieterman ED; Reiss P; Cannegieter SC; Lijfering WM; Meijer K; Bierman W; Tichelaar V; Rijnders BJA;
    PLoS Med; 2020 May; 17(5):e1003101. PubMed ID: 32407386
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effect of statins on mortality and cardiovascular disease in primary care hypertensive patients without other cardiovascular disease or diabetes.
    Andersson T; Nåtman J; Mourtzinis G; Bager JE; Bengtsson Boström K; Franzén S; Hjerpe P
    Eur J Prev Cardiol; 2023 Nov; 30(17):1883-1894. PubMed ID: 37368941
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Time trends in statin use and incidence of recurrent cardiovascular events in secondary prevention between 1999 and 2013: a registry-based study.
    Laleman N; Henrard S; van den Akker M; Goderis G; Buntinx F; Van Pottelbergh G; Vaes B
    BMC Cardiovasc Disord; 2018 Nov; 18(1):209. PubMed ID: 30400778
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Statin Prescribing Patterns: An Analysis of Data From Patients With Diabetes in the National Hospital Ambulatory Medical Care Survey Outpatient Department and National Ambulatory Medical Care Survey Databases, 2005-2010.
    Pauff BR; Jiroutek MR; Holland MA; Sutton BS
    Clin Ther; 2015 Jun; 37(6):1329-39. PubMed ID: 25869626
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cholesterol treatment with statins: who is left out and who makes it to goal?
    Franks P; Tancredi D; Winters P; Fiscella K
    BMC Health Serv Res; 2010 Mar; 10():68. PubMed ID: 20236527
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.
    Zhou Z; Rahme E; Pilote L
    Am Heart J; 2006 Feb; 151(2):273-81. PubMed ID: 16442888
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of Rosuvastatin Therapy on Biomarkers of Inflammation and Immune Activation in People With Human Immunodeficiency Virus at Intermediate Cardiovascular Risk.
    Hearps AC; Angelovich TA; Trevillyan JM; Wong ME; Calmy A; Hoy JF; Jaworowski A
    J Infect Dis; 2021 Aug; 224(4):667-672. PubMed ID: 34398237
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Patients Living With HIV Are Less Likely to Receive Appropriate Statin Therapy for Cardiovascular Disease Risk Reduction.
    Emmons RP; Hastain NV; Miano TA; Schafer JJ
    J Pharm Pract; 2022 Aug; 35(4):568-572. PubMed ID: 33678059
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impaired response of memory Treg to high density lipoproteins is associated with intermediate/high cardiovascular disease risk in persons with HIV.
    Atehortua L; Baig M; Morris J; Trentman S; Davidson WS; Fichtenbaum CJ; Chougnet CA
    Front Immunol; 2023; 14():1146624. PubMed ID: 36969259
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Trends in Racial and Ethnic Disparities in Antiretroviral Therapy Prescription and Viral Suppression in the United States, 2009-2013.
    Beer L; Bradley H; Mattson CL; Johnson CH; Hoots B; Shouse RL;
    J Acquir Immune Defic Syndr; 2016 Dec; 73(4):446-453. PubMed ID: 27391389
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Race and Socioeconomic Differences Associated With Changes in Statin Eligibility Under the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines.
    Verma AA; Jimenez MP; Subramanian SV; Sniderman AD; Razak F
    Circ Cardiovasc Qual Outcomes; 2017 Sep; 10(9):. PubMed ID: 28912201
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risk of Acute Liver Injury After Statin Initiation by Human Immunodeficiency Virus and Chronic Hepatitis C Virus Infection Status.
    Byrne DD; Tate JP; Forde KA; Lim JK; Goetz MB; Rimland D; Rodriguez-Barradas MC; Butt AA; Gibert CL; Brown ST; Bedimo R; Freiberg MS; Justice AC; Kostman JR; Roy JA; Lo Re V
    Clin Infect Dis; 2017 Oct; 65(9):1542-1550. PubMed ID: 29020184
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.
    Elam MB; Ginsberg HN; Lovato LC; Corson M; Largay J; Leiter LA; Lopez C; O'Connor PJ; Sweeney ME; Weiss D; Friedewald WT; Buse JB; Gerstein HC; Probstfield J; Grimm R; Ismail-Beigi F; Goff DC; Fleg JL; Rosenberg Y; Byington RP;
    JAMA Cardiol; 2017 Apr; 2(4):370-380. PubMed ID: 28030716
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Racial and ethnic disparities in coronavirus disease 2019 disease incidence independent of comorbidities, among people with HIV in the United States.
    Bender Ignacio RA; Shapiro AE; Nance RM; Whitney BM; Delaney JAC; Bamford L; Wooten D; Karris MY; Mathews WC; Kim HN; Keruly J; Burkholder G; Napravnik S; Mayer KH; Jacobson J; Saag M; Moore RD; Eron JJ; Willig AL; Christopoulos KA; Martin J; Hunt PW; Crane HM; Kitahata MM; Cachay ER;
    AIDS; 2022 Jul; 36(8):1095-1103. PubMed ID: 35796731
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Achievement of LDL-cholesterol goal with statins after an st segment elevation myocardial infarction.
    Tungsubutra W; Phongtuntakul B
    J Med Assoc Thai; 2015 Feb; 98(2):129-36. PubMed ID: 25842792
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A systematic review and economic evaluation of statins for the prevention of coronary events.
    Ward S; Lloyd Jones M; Pandor A; Holmes M; Ara R; Ryan A; Yeo W; Payne N
    Health Technol Assess; 2007 Apr; 11(14):1-160, iii-iv. PubMed ID: 17408535
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Assessing statin effects on cardiovascular pathways in HIV using a novel proteomics approach: Analysis of data from INTREPID, a randomized controlled trial.
    Toribio M; Fitch KV; Stone L; Zanni MV; Lo J; de Filippi C; Sponseller CA; Lee H; Grundberg I; Thompson MA; Aberg JA; Grinspoon SK
    EBioMedicine; 2018 Sep; 35():58-66. PubMed ID: 30174281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.